Results 21 to 30 of about 29,580 (292)
Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]
, 2016 In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven +1 more
core +3 more sources
Trends in overall mortality among US veterans with primary myelofibrosis
BMC Cancer, 2023 Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 ...
Tsewang Tashi +5 more
doaj +1 more source
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
Frontiers in Endocrinology, 2023 Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose
Douglas Tremblay +3 more
doaj +1 more source
A key role for leukemia inhibitory factor in C26 cancer cachexia [PDF]
, 2015 Cachexia is an exacerbating event in many types of cancer that is strongly associated with a poor prognosis. We have identified cytokine, signaling, and transcription factors that are required for cachexia in the mouse C26 colon carcinoma model of cancer.
Jackman, Robert W. +2 more
core +1 more source
Experimental and Therapeutic Medicine, 2013 The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
GU, LIAN +8 more
openaire +3 more sources
Journal of Hematology & Oncology, 2017 Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Srdan Verstovsek +13 more
doaj +1 more source
COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
European Journal of Inflammation, 2021 We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG).
Claudio Ucciferri +4 more
doaj +1 more source
Recent progress of JAK inhibitors for hematological disorders
Immunological Medicine, 2023 JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both ...
Keita Kirito
doaj +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
Haematologica, 2019 Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity.
Alicia Arenas Cortés +11 more
doaj +1 more source